Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

82 results
Display

Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study

Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW

Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma

Kwan BS, Kim JH, Park SJ, Choe WH, Kwon SY, Yoo BC

Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

Tamaki N, Kurosaki M, Loomba R, Izumi N

An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study

Jeong JY, Jun DW, Park SJ, Sohn JH, Kim SG, Lee SW, Jeong SW, Kim MY, Kim W, Shim JJ, Kim HS, Suk KT, Ahn SB

Background/Aims: We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC). Methods: Our...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C

Na SK, Song BC

Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach

Barakat NH, Barakat SH, Ahmed N

OBJECTIVES: The aim of this study is to develop an intelligent diagnostic system utilizing machine learning for data cleansing, then build an intelligent model and obtain new cutoff values for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Huang CF, Yu ML

During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato , Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H

BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis

Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS

BACKGROUND/AIMS: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. METHODS: We performed a single-arm, multicenter prospective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Ko SY, Choe WH

The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?

Yeon JE

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

The Korean Association for the Study of the Liver (KASL)

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Use of sofosbuvir in chronic kidney disease: Is it necessary?

Lim TS, Ahn SH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Quality of Life of Chronic Hepatitis C Patients and Its Associated Factors

Cho HJ, Park E

OBJECTIVES: This study aimed to investigate the factors affecting the health-related quality of life (HRQOL) of patients with chronic hepatitis C (CHC). METHODS: This study is based on a descriptive survey...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Illness Experience of Patients with Chronic Hepatitis C Participating in Clinical Trials

Cho HJ, Park E

Objectives To understand the illness experience of patients with chronic hepatitis C participating in clinical trials in the sociocultural context of Korea in an in-depth and comprehensive manner. Methods A focused ethnography approach...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chronic hepatitis C healed by peginterferon-α and rivabirin treatment after kidney transplantation

Seok MG, Lee TH, Yun SR, Hwang WM, Yoon SH, Choe IS, Kang SJ, Hong JY, Kim DS

Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant recipients, HCV infected kidney recipient have higher prevalence of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study

Zeng QL, Li B, Zhang XX, Chen Y, Fu YL, Lv J, Liu YM, Yu ZJ

BACKGROUND/AIMS: No clinical model exists to predict the occurrence of hepatocellular carcinoma in sustained virologic response-achieving (HCC after SVR) patients with chronic hepatitis C (CHC). METHODS: We performed a case-control study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C

Kim MN, Kim HS, Kim JK, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH

Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3

Jung YK

Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1

Park SH

The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr